Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...
Parallel programming exploits the capabilities of multicore systems by dividing computational tasks into concurrently executed subtasks. This approach is fundamental to maximising performance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback